Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2007

View Archived Issues

Novartis reports pipeline and business highlights of first quarter

Therapeutic autophagy by small-molecule enhancers shows promise for neurodegenerative diseases

Recent Bayer patent describes new treatment option for thrombotic disorders

Recent Pharmaleads and Pfizer patents disclose novel analgesic agents

Novel antimalarial agents disclosed in recent patent literature

Novel arylhydrocarbon receptor antagonist may protect against skin photodamage

Recent Valeant and Medivir patents report novel agents for HIV infection

Gene Logic seeks new development paths for Abbott drugs

Update on Memryte program in Alzheimer's

Phase I findings on S. aureus vaccine

ReNeuron forms collaboration to develop c-mycERstem cell expansion technology

ReAble Therapeutics to acquire Iomed

FDA Advisory Committee votes in favor of ACAM-2000

New phase II trial studies DNB-001 for ocular hypertension

Novartis defends Lotrel patent against Teva generic

Ortho Biotech Products to return BMP-7 program to Curis

Ty-800 typhoid vaccine shows clinical potential

Wex seeks clearance for Canadian study of Tectin

Sun Pharmaceutical to acquire Taro

TRO-19622 begins phase II trial in painful diabetic neuropathy

Towards new additions to the therapeutic armamentarium in psoriasis

Prous Science publishes new report on tuberculosis

FDA approves Velcade + Doxil for relapsed/refractory multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...